The risk of COVID-19 severity in patients with ms appears to be associated with immunotherapy
Immunomodulatory drugs are important to control disease activity in relapsing-remitting multiple sclerosis (MS). Anti-CD 20-therapy is one of such medications. In Sweden, extensive off label prescription of rituximab (RTX) in MS has been documented; it is presently prescribed for more than half of a...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
FBSI “Federal Scientific Center for Medical and Preventive Health Risk Management Technologies”
2021-09-01
|
| Series: | Analiz Riska Zdorovʹû |
| Subjects: | |
| Online Access: | https://journal.fcrisk.ru/eng/2021/3/14 |